-88%

est. 2Y upside i

HealthcareSeries A

DNA App Store

Rank

#4278

Sector

Healthcare & Digital Health

Est. Liquidity

~3Y

Data Quality

Data: Low

Genomelink presents a high-risk equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (10%)+150%

Genomelink successfully expands its 'DNA App Store' ecosystem, attracting a significant user base by offering unique, highly accurate, and actionable insights that differentiate it from incumbents. This leads to strong subscription growth and a strategic acquisition at a valuation of $95M within two years, representing a 2.5x return.

Base (40%)-20%

Genomelink maintains its niche, but struggles to significantly grow market share against dominant incumbents like 23andMe and Ancestry, and faces ongoing challenges with customer satisfaction and report accuracy. The company's valuation slightly declines to $30.4M, resulting in a -20% return for equity holders over two years.

Bear (50%)-80%

Increased competition from incumbents, coupled with persistent negative customer feedback (including BBB complaints) and the inherent limitations of raw DNA data analysis, severely hampers Genomelink's growth and user acquisition. The company is forced into a distressed sale or down round, leading to a valuation of $7.6M, effectively wiping out most common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Funding Intensity

24%

Investors hold $9M in liquidation preferences ahead of common stock, representing 23.7% of the current $38M valuation.

Dilution Risk

high

As an early-stage company with $9M in total funding, Genomelink will likely require additional significant funding rounds, which will dilute existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Genomelink's equity.

Questions to Ask at the Interview

Strategic questions based on Genomelink's data — designed to show you've done your homework.

  • 1

    “How does Genomelink plan to effectively compete and differentiate its 'DNA App Store' against the comprehensive offerings and massive user bases of incumbents like 23andMe and Ancestry, especially given their direct access to raw DNA data?”

  • 2

    “What specific strategies are in place to address the recurring customer complaints regarding report accuracy, value of premium features, and customer service, particularly in light of the 'F' rating from the Better Business Bureau?”

  • 3

    “Given the company's early stage and $9M in total funding, what is the anticipated timeline and strategy for future funding rounds, and how will potential dilution for common stock holders be managed?”

Community

Valuation Sentiment

Our model estimates -88% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.